Covered recipient · General Payments record
PRASANTHI KANDULA
Allopathic & Osteopathic Physicians Dermatology Procedural Dermatology
General Payments · PY2018–2024
$5,520.75
- Reported across 198 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $494.15 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Galderma Laboratories, L.P. | $116.75 | 2 |
| REVANCE THERAPEUTICS, INC. | $95.17 | 2 |
| Janssen Biotech, Inc. | $94.97 | 4 |
| ABBVIE INC. | $92.07 | 4 |
| PFIZER INC. | $33.84 | 1 |
| UCB, Inc. | $23.76 | 1 |
| E.R. Squibb & Sons, L.L.C. | $22.13 | 1 |
| Incyte Corporation | $15.46 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $30.72 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104026479 | CMS |
| ABBVIE INC. | $17.14 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104026481 | CMS |
| ABBVIE INC. | $26.93 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104026483 | CMS |
| ABBVIE INC. | $17.28 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104026485 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.13 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1101744515 | CMS |
| Galderma Laboratories, L.P. | $56.37 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145307417 | CMS |
| Galderma Laboratories, L.P. | $60.38 | 10/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145307419 | CMS |
| Incyte Corporation | $15.46 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141313903 | CMS |
| Janssen Biotech, Inc. | $32.53 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078794816 | CMS |
| Janssen Biotech, Inc. | $21.34 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078796451 | CMS |
| Janssen Biotech, Inc. | $19.42 | 06/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078795370 | CMS |
| Janssen Biotech, Inc. | $21.68 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078795386 | CMS |
| PFIZER INC. | $33.84 | 06/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1130916136 | CMS |
| REVANCE THERAPEUTICS, INC. | $27.01 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147921356 | CMS |
| REVANCE THERAPEUTICS, INC. | $68.16 | 08/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147921358 | CMS |
| UCB, Inc. | $23.76 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143135453 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.